Top 5 Diagnostics Stocks in India You Should Know
The following table provides a detailed snapshot of key diagnostics stocks in India, ranked by their market capitalisation. These companies are involved in diagnostic services across segments such as pathology, radiology, and life sciences.
Company Name
| Last Price (₹)
| % Change
| 52-Week High (₹)
| 52-Week Low (₹)
| Market Cap (₹ Cr)
| Segment
|
Dr Lal PathLabs
| 2,478.10
| -0.85
| 3,645.00
| 2,168.80
| 20,714.87
| Hospital & Healthcare Services
|
Vijaya Diagnostic
| 1,001.00
| 0.02
| 1,276.75
| 629.15
| 10,273.89
| Hospital & Healthcare Services
|
Metropolis
| 1,562.60
| -1.51
| 2,306.85
| 1,530.10
| 8,013.19
| Hospital & Healthcare Services
|
Thyrocare Tech
| 683.40
| -2.48
| 1,053.05
| 570.75
| 3,621.57
| Hospital & Healthcare Services
|
Suraksha Diagnostic
| 257.80
| -1.47
| 449.00
| 233.15
| 1,342.64
| Labs & Life Sciences Services
|
Source: MoneyControl as of 31 Mar’25
Overview of Diagnostics Stocks
This summary table highlights the top diagnostics players based on their overall market capitalisation, offering a quick comparison.
Company Name
| Market Cap (₹ Cr)
|
Dr Lal PathLabs
| 20,714.87
|
Vijaya Diagnostic
| 10,273.89
|
Metropolis
| 8,013.19
|
Thyrocare Tech
| 3,621.57
|
Suraksha Diagnostic
| 1,342.64
|
Source: MoneyControl
Dr Lal PathLabs
Dr Lal PathLabs Ltd operates as one of the leading diagnostic service providers in India. The company operates from New Delhi while providing a broad selection of tests through their laboratory facilities and sample collection points. The organization maintains its growth strategy through both international market penetration and operational performance improvements.
Dr Lal PathLabs – Financial Overview
Metric
| Value
|
Market Capitalisation (₹ Cr)
| 20,720
|
Last Price (₹)
| 2,478.80
|
52-Week High (₹)
| 3,653.95
|
52-Week Low (₹)
| 2,165.80
|
TTM PE Ratio
| 49.72
|
TTM EPS (₹)
| 49.86 (+16.36% YoY)
|
P/B Ratio
| 10.36
|
Book Value Per Share (₹)
| 239.45
|
Dividend Yield (%)
| 0.97
|
Return on Equity (%)
| 19.34
|
Debt to Equity Ratio
| 0.05
|
Latest Quarterly Revenue
| ₹596.70 Cr (Q3 FY25)
|
Source: MoneyControl
Highlights
● Q3 FY25 net sales up 10.73% YoY.
● Minimal debt and stable ROE.
● Promoter holding slightly reduced to 53.91% in Dec 2024.
Metropolis Healthcare
Metropolis Healthcare Ltd. operates as a major diagnostic company that delivers specialized testing services between pathology and molecular diagnostics. Through acquisitions Metropolis Healthcare Ltd. continues to expand while maintaining a wide network of facilities throughout major urban areas.
Metropolis Healthcare – Financial Overview
Metric
| Value
|
Market Capitalisation (₹ Cr)
| 8,023.19
|
Last Price (₹)
| 1,564.55
|
52-Week High (₹)
| 2,318.30
|
52-Week Low (₹)
| 1,527.60
|
TTM PE Ratio
| 52.70
|
TTM EPS (₹)
| 29.69 (+19.00% YoY)
|
P/B Ratio
| 6.78
|
Book Value Per Share (₹)
| 230.87
|
Dividend Yield (%)
| 0.26
|
Return on Equity (%)
| 11.66
|
Debt to Equity Ratio
| 0.00
|
Latest Quarterly Revenue
| ₹296.88 Cr (Q3 FY25)
|
Source: MoneyControl
Highlights
● Debt-free business with expansion via M&A (e.g., Scientific Pathology, Core Diagnostics).
● Q3 revenue rose over 10% YoY.
● 1-year price return at -9.23% with sharp YTD correction.
Vijaya Diagnostic Centre
Vijaya Diagnostic Centre Ltd. operates the biggest diagnostic network throughout South India by providing pathology and radiology services. The company operates debt-free while expanding its operations through its strong presence in both Tier I and II cities.
Vijaya Diagnostic – Financial Overview
Metric
| Value
|
Market Capitalisation (₹ Cr)
| 10,337.53
|
Last Price (₹)
| 1,007.20
|
52-Week High (₹)
| 1,275.00
|
52-Week Low (₹)
| 636.60
|
TTM PE Ratio
| 78.08
|
TTM EPS (₹)
| 12.90 (+15.49% YoY)
|
P/B Ratio
| 14.44
|
Book Value Per Share (₹)
| 69.77
|
Dividend Yield (%)
| 0.10
|
Return on Equity (%)
| 17.54
|
Debt to Equity Ratio
| 0.00
|
Latest Quarterly Revenue
| ₹168.98 Cr (Q3 FY25)
|
Source: MoneyControl
Highlights
● Net sales up 27.35% YoY in Q3 FY25.
● Trades at high P/E and P/B multiples.
● Promoter holding steady at 53.91% as of Dec 2024.
Thyrocare Technologies
The diagnostic chain Thyrocare Technologies Ltd. provides automated processing services and focuses on preventive care testing for wellness purposes as it operates internationally. The company expanded its operations through new East African ventures in recent times.
Thyrocare Technologies – Financial Overview
Metric
| Value
|
Market Capitalisation (₹ Cr)
| 3,601.70
|
Last Price (₹)
| 679.65
|
52-Week High (₹)
| 1,055.00
|
52-Week Low (₹)
| 571.40
|
TTM PE Ratio
| 41.07
|
TTM EPS (₹)
| 16.55 (+23.84% YoY)
|
P/B Ratio
| 7.38
|
Book Value Per Share (₹)
| 92.12
|
Dividend Yield (%)
| 2.65
|
Return on Equity (%)
| 13.43
|
Debt to Equity Ratio
| 0.04
|
Latest Quarterly Revenue
| ₹165.92 Cr (Q3 FY25)
|
Source: MoneyControl
Highlights
● Consolidated Q3 revenue up 23.14% YoY.
● Dividend yield of 2.65% among the highest in the peer group.
● Promoter holding slightly reduced to 71.06% in Dec 2024.
Suraksha Diagnostic
Suraksha Diagnostic Ltd. is a relatively new listed player in diagnostics, with a base in Eastern India. It focuses on both pathology and imaging services. While it maintains moderate valuations, it has shown strong top-line growth.
Suraksha Diagnostic – Financial Overview
Metric
| Value
|
Market Capitalisation (₹ Cr)
| 1,349.93
|
Last Price (₹)
| 259.20
|
52-Week High (₹)
| 449.00
|
52-Week Low (₹)
| 231.00
|
TTM PE Ratio
| 43.34
|
TTM EPS (₹)
| 5.98 (-98.22% YoY)
|
P/B Ratio
| 6.78
|
Book Value Per Share (₹)
| 38.25
|
Return on Equity (%)
| 13.28
|
Debt to Equity Ratio
| 0.05
|
Latest Quarterly Revenue
| ₹59.51 Cr (Q3 FY25)
|
Source: MoneyControl
Highlights
● Q3 net sales up 14.84% YoY.
● Publicly listed recently with growing institutional visibility.
● Promoter holding stable at 48.78% in Dec 2024.
How To Invest In Diagnostics Stocks?
Investing in diagnostics stocks involves several steps:
1. Open a Demat Account: To hold shares electronically, you need a demat account.
2. Set Up a Trading Account: This account allows you to buy and sell stocks on exchanges.
3. Research Stocks: Analyze various diagnostics companies based on financial performance, market position, and growth potential.
4. Use a Brokerage Calculator: This tool helps estimate transaction costs associated with buying or selling stocks.
5. Consider MTF (Margin Trading Facility): For those looking to leverage their investments, MTF can provide additional capital for purchasing stocks.
6. Monitor Market Trends: Stay informed about industry developments and adjust your investment strategy accordingly.
By following these steps, investors can effectively navigate the diagnostics stock market and make informed decisions.
Conclusion
The Indian diagnostics industry continues to expand rapidly because of growing healthcare service requirements and government backing. The current market growth makes diagnostics stocks an appealing investment opportunity for investors who want to capitalise on this trend. The market sector functions as a tempting investment choice because it benefits from technological advances combined with increasing health-related knowledge and stable market dynamics.
Before investing it is crucial to use a brokerage calculator for cost estimation and to create trading and demat accounts for smooth transactions. To boost their investment potential investors also need to stay updated on market trends. It helps to develop strategies such as MTF (Margin Trading Facility) and intraday trading.
Other Popular Stocks in India
Here are some additional listed diagnostics-related companies in India:
● Krsnaa Diagnostics
Operates an extensive network focused on radiology and pathology services across public-private partnerships.
● Vimta Labs
Offers specialised services in clinical research and contract laboratory testing, serving both domestic and global clients.
● Medinova Diagnostic Services
One of the earlier players in the Indian diagnostics sector, with operations in select regions.
● Narayana Hrudayalaya (diagnostics revenue segment)
While primarily a hospital chain, it operates in-house diagnostic labs contributing to overall healthcare services.